drugset / Trial / NCT00663169

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

NCT00663169

Phase 2 Completed 6 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This is an exploratory proof-of-concept study to evaluate the safety and efficacy of canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.

Timeline

Start
2008-04
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 10 mg/kg Intravenous
Comparator Dexamethasone Small molecule 12 mg Intravenous

Indications